Topics:

Hematologic Malignancies

Hematologic Malignancies

Researchers have identified patient factors linked with the discontinuation of ibrutinib therapy for reasons other than disease progression.

The FDA has approved panobinostat (Farydak), in combination with bortezomib and dexamethasone, for treating patients with multiple myeloma.

New data indicates that the order in which people acquired certain somatic mutations influenced several clinical features of myeloproliferative neoplasms.

The FDA has expanded the use of oral lenalidomide in multiple myeloma to include its use in combination with dexamethasone for newly diagnosed patients.

A new study suggests that cancer patients do not often request unnecessary and sometimes costly tests or treatments.

A new study finds that childhood cancer survivors are at risk for pituitary hormone deficiencies after radiotherapy treatment to the head.

Despite an association with improved survival, elderly DLBCL patients are less likely to receive standard-of-care chemotherapy with R-CHOP.

Pages

Subscribe to Hematologic Malignancies on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.